DANAHER CORPORATION's ticker is DHR and the CUSIP is 235851102. A total of 2,042 filers reported holding DANAHER CORPORATION in Q3 2023. The put-call ratio across all filers is 0.89 and the average weighting 0.6%.
About DANAHER CORPORATION
Danaher Corporation is a global science and technology company that designs, manufactures, and markets innovative products and services to professional, medical, industrial, and commercial customers. The company operates through four segments: Life Sciences, Diagnostics, Dental, and Environmental & Applied Solutions.
Danaher's Life Sciences segment provides a range of research tools to scientists around the world, including mass spectrometry, chromatography, and automation systems. The Diagnostics segment offers a broad range of diagnostic products, including clinical chemistry, immunoassay, microbiology, and molecular diagnostic systems. The Dental segment provides a range of dental equipment and consumables, including imaging systems, dental instruments, and consumables. The Environmental & Applied Solutions segment offers a range of products and services to help customers protect the environment and improve productivity.
Danaher has a strong track record of growth and innovation, driven by its focus on continuous improvement and customer satisfaction. The company has a culture of operational excellence, which has enabled it to consistently deliver high-quality products and services to its customers. Danaher's management team is highly experienced and has a proven track record of creating value for shareholders.
In conclusion, Danaher Corporation is a well-established and innovative company that is well-positioned to continue delivering strong growth and value to its shareholders. With its focus on operational excellence and customer satisfaction, Danaher is a company that investors should keep an eye on.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $239,965,081 | +13.0% | 977,623 | +10.4% | 0.34% | +6.9% |
Q2 2023 | $212,434,134 | -49.1% | 885,439 | -46.6% | 0.32% | -53.6% |
Q1 2023 | $417,511,272 | -49.8% | 1,656,853 | -47.2% | 0.69% | -52.6% |
Q4 2022 | $832,122,465 | -27.0% | 3,135,130 | -29.0% | 1.45% | -32.8% |
Q3 2022 | $1,140,475,000 | +13.2% | 4,414,588 | +11.1% | 2.16% | +18.9% |
Q2 2022 | $1,007,316,000 | -0.5% | 3,973,559 | +15.2% | 1.81% | +19.5% |
Q1 2022 | $1,012,870,000 | +0.7% | 3,449,768 | +12.6% | 1.52% | +6.3% |
Q4 2021 | $1,005,983,000 | +18.8% | 3,062,581 | +10.2% | 1.43% | +5.7% |
Q3 2021 | $846,674,000 | +60.5% | 2,780,204 | +41.4% | 1.35% | +57.7% |
Q2 2021 | $527,597,000 | +20.9% | 1,965,642 | +1.4% | 0.86% | +6.6% |
Q1 2021 | $436,296,000 | -17.9% | 1,938,416 | -19.5% | 0.80% | -28.7% |
Q4 2020 | $531,682,000 | +21.1% | 2,409,228 | +18.2% | 1.13% | +6.9% |
Q3 2020 | $439,061,000 | +5.3% | 2,039,082 | -13.5% | 1.05% | -8.0% |
Q2 2020 | $416,815,000 | +28.1% | 2,357,237 | +0.3% | 1.14% | +4.0% |
Q1 2020 | $325,290,000 | -35.4% | 2,350,062 | -28.7% | 1.10% | -16.6% |
Q4 2019 | $503,889,000 | -13.0% | 3,296,816 | -17.8% | 1.32% | -23.6% |
Q3 2019 | $579,109,000 | +12.7% | 4,010,886 | +11.5% | 1.73% | +8.8% |
Q2 2019 | $513,871,000 | +9.2% | 3,595,991 | +0.9% | 1.59% | +3.8% |
Q1 2019 | $470,486,000 | +53.7% | 3,563,976 | +18.6% | 1.53% | +28.8% |
Q4 2018 | $306,110,000 | +8.7% | 3,005,233 | +16.0% | 1.19% | +18.6% |
Q3 2018 | $281,618,000 | +20.4% | 2,591,731 | +9.3% | 1.00% | +15.9% |
Q2 2018 | $233,949,000 | +29.8% | 2,370,808 | +23.7% | 0.86% | +23.8% |
Q1 2018 | $180,280,000 | +45.4% | 1,916,513 | +43.5% | 0.70% | +46.9% |
Q4 2017 | $123,967,000 | +20.7% | 1,335,453 | +11.6% | 0.48% | +11.5% |
Q3 2017 | $102,667,000 | +5.6% | 1,196,867 | +3.9% | 0.43% | -5.3% |
Q2 2017 | $97,210,000 | -8.3% | 1,151,926 | -7.1% | 0.45% | -6.8% |
Q1 2017 | $106,034,000 | +17.6% | 1,239,707 | +7.0% | 0.48% | +11.0% |
Q4 2016 | $90,178,000 | – | 1,158,532 | – | 0.44% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
ARTHUR M. COHEN & ASSOCIATES, LLC | 217,436 | $53,823,432 | 13.80% |
Defender Capital, LLC. | 152,962 | $37,949,802 | 13.74% |
Bancreek Capital Management, LP | 60,890 | $15,106,809 | 13.58% |
BOONE CAPITAL MANAGEMENT LLC | 129,163 | $32,045,340 | 10.11% |
Eagle Health Investments LP | 175,085 | $43,438,589 | 9.57% |
Third Point | 2,450,000 | $607,845,000 | 9.22% |
Clio Asset Management LLC | 41,695 | $10,344,530 | 9.04% |
Consulta Ltd | 500,000 | $124,050,000 | 8.91% |
Riverstone Advisors, LLC | 47,960 | $11,799,701 | 8.16% |
CADEN CAPITAL PARTNERS, LP | 123,755 | $27,215,377 | 7.66% |